NeuroPace, Inc. (NPCE) fair value analysis
Nasdaq · Updated 2026-10-19
NPCE price how computed
Valuation status
No fair-value estimate yetNPCE has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for NPCE yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $12.24
- Sector
- Healthcare
- 12-month range
- $9.40–$19.29
- Market cap
- $420M
- From 52-week high
- -36.5%
- Shares outstanding
- 34.3M
- Rank in Healthcare by quality score
- #166 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
NeuroPace, Inc. is a medical device company that develops and commercializes neurostimulation technology designed to treat neurological disorders, primarily epilepsy. The company operates in the United States and serves patients through a network of healthcare providers and medical institutions.
NPCE currently ranks #166 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $420M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $98.8M
- Net margin
- -19.3%
- EPS (TTM)
- $-0.57
- Gross margin
- 82.8%
- Debt / equity
- 5.88
- Revenue growth (3-yr avg)
- 13.0%
- Shares outstanding
- 34.3M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 34 · neutral
- 50-day average
- $14.01
- 200-day average
- $15.15
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+5.3%)
2026-03 ▲ beat (+13.6%)
2025-12 ▲ beat (+46.7%)
2025-09 ▲ beat (+42.1%)
2025-06 ▼ miss (-18.2%)
2025-03 ▲ beat (+12.5%)
2024-12 ▲ beat (+19.4%)
2024-09 ▲ beat (+29.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 0 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $20
- Target vs last price
- +63.4%
What our data shows for NPCE
- Shares are trading in the lower third of their 12-month price range of $9.40–$19.29.
- The 14-day relative strength index sits at a neutral 34.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- NPCE's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the NPCE conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is NPCE stock undervalued?
TickrTrends has no fair-value estimate for NPCE yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is NPCE's TickrTrends verdict?
NPCE is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does NPCE compare to other Healthcare stocks?
NPCE ranks #166 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is NPCE overbought or oversold?
NPCE's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does NPCE report earnings next?
NPCE's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does NPCE usually beat earnings estimates?
Over its last 8 reported quarters NPCE beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about NPCE?
Of 10 analysts covering NPCE, 10 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $20 (+63.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.